Department of Endocrinology, Beijing Ruijing Diabetes Hospital, Beijing, China.
Department of Endocrinology, Heilongjiang Ruijing Diabetes Hospital, Haerbin, China.
Front Endocrinol (Lausanne). 2022 Jan 19;12:723720. doi: 10.3389/fendo.2021.723720. eCollection 2021.
This study aimed to explore the relationship between short-term (≤12 months) changes in the estimated glomerular filtration rate (eGFR) and hemoglobin A (HbA) in patients with type 2 diabetes (T2D).
A total of 2,599 patients with T2D were enrolled if they were registered in the Diabetes Sharecare Information System, were aged 18-75 years, and had 2-3 HbA and eGFR measurements within the preceding 12 months. The studied patients were categorized into five groups based on eGFR, i.e., the relatively stable (RS), fast decline (FD), modest decline (MD), modest increase (MI), and fast increase (FI) groups.
The median eGFR changes from baseline were -22.14, -6.44, 0.00, 6.32, and 20.00 ml/min per 1.73 m for patients in the FD, MD, RS, MI, and FI groups, respectively. Up to 1,153 (44.4%) subjects experienced an eGFR decline of ≥3.5 ml/min per 1.73 m, including 821 (31.6%) FD subjects and 332 (12.8%) MD subjects. A decreased trend was found between the eGFR change and HbA decrease category, even after multivariable adjustment. In general, an eGFR FD was frequently found in patients who had an HbA reduction of ≥3.00% and a baseline HbA ≥8.0%; alternatively, such a result was also observed for a urinary albumin-to-creatinine ratio (UACR) of 30.0-300.0 mg/g, regardless of a diabetes duration of <10.0 or ≥10.0 years, or in patients who had an HbA reduction of ≥1.00% accompanied by hyperfiltration.
Some patients with T2D experienced an eGFR FD or MD during the ≤12-month follow-up period. A significant downward trend in eGFR change was demonstrated alongside an HbA reduction, independent of UACR stage, diabetes duration, and hyperfiltration. Sustained monitoring and cautious interpretation of the HbA and eGFR changes will be needed in clinical practice.
本研究旨在探讨 2 型糖尿病(T2D)患者短期(≤12 个月)内估算肾小球滤过率(eGFR)和血红蛋白 A(HbA)变化之间的关系。
共纳入 2599 例在糖尿病共享信息系统中登记的年龄在 18-75 岁之间且在过去 12 个月内有 2-3 次 HbA 和 eGFR 测量值的 T2D 患者。根据 eGFR 将研究患者分为五组,即相对稳定(RS)、快速下降(FD)、适度下降(MD)、适度升高(MI)和快速升高(FI)组。
从基线开始,FD、MD、RS、MI 和 FI 组患者的 eGFR 中位数变化分别为-22.14、-6.44、0.00、6.32 和 20.00 ml/min/1.73 m。多达 1153 例(44.4%)患者的 eGFR 下降≥3.5 ml/min/1.73 m,其中 821 例(31.6%)为 FD 患者,332 例(12.8%)为 MD 患者。即使在多变量调整后,eGFR 变化与 HbA 降低类别之间也呈下降趋势。一般来说,eGFR FD 常见于 HbA 降低≥3.00%且基线 HbA≥8.0%的患者;或者,在 UACR 为 30.0-300.0 mg/g 的情况下,也会出现这种结果,而与糖尿病病程<10.0 或≥10.0 年,或 HbA 降低≥1.00%伴高滤过无关。
在≤12 个月的随访期间,一些 T2D 患者经历了 eGFR FD 或 MD。eGFR 变化呈显著下降趋势,与 HbA 降低相关,与 UACR 分期、糖尿病病程和高滤过无关。在临床实践中需要持续监测和谨慎解释 HbA 和 eGFR 的变化。